Opendata, web and dolomites

ZIKAVAX SIGNED

Fast track development of a Zika vaccine based on measles vector

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ZIKAVAX project word cloud

Explore the words cloud of the ZIKAVAX project. It provides you a very rough idea of what is the project "ZIKAVAX" about.

adaptability    complications    demonstrated    epidemiological    ultimate    mosquito    atomique    commissariat    issue    therapies    regions    world    borne    yield    mice    declared    clinical    emergency    1947    standard    primates    track    safety    rapid    urgent    bioscience    infectious    virus    platform    demonstration    zika    energie    innovative    safe    unaffected    immunisation    affordable    effectiveness    vector    variety    record    human    brain    pathogens    agrave    vaccines    proof    preclinical    severe    borns    consequently    organization    diseases    immunogenicity    institut    trial    purity    spread    pasteur    give    health    antigen    previously    model    outbreak    date    zikavax    measles    expression    candidate    vaccine    malformations    congenital    treatments    committed    neurological    truly    adults    recombinant    public    infection    adult    themis    manufacturing    ia    disease    flavivirus    nor    humans    isolated    volunteers    preventive   

Project "ZIKAVAX" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN VACCINE INITIATIVE EWIV 

Organization address
address: VOSSSTRASSE 2 GEB 4040
city: HEIDELBERG
postcode: 69115
website: http://www.euvaccine.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.zikavax.eu
 Total cost 4˙918˙137 €
 EC max contribution 4˙918˙137 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN VACCINE INITIATIVE EWIV DE (HEIDELBERG) coordinator 673˙968.00
2    THEMIS BIOSCIENCE GMBH AT (WIEN) participant 3˙192˙862.00
3    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 562˙290.00
4    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 489˙016.00

Map

 Project objective

Zika virus is an emerging mosquito-borne flavivirus. Although already isolated in 1947, to date there are no specific treatments nor any vaccines available against Zika virus disease, making it a truly neglected infectious disease. The recent rapid spread of the Zika virus in previously unaffected regions has provided strong epidemiological evidence that infection with this virus might be associated with neurological complications in adults and with an increase in severe congenital brain malformations of new-borns. Consequently, the World Health Organization has declared the recent outbreak of the Zika virus a public health emergency. The ZIKAVAX proposal has the objective to address this urgent public health issue by promoting the rapid development of a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX will use a delivery platform technology based on a measles vaccine vector with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. The manufacturing process for these measles vector-based vaccines has been developed to give high yield and purity using standard equipment. In ZIKAVAX, following antigen selection and expression, immunisation studies will be conducted with the Zika vaccine candidate in mice and in a challenge model in non-human primates that will developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate in adult volunteers in a phase Ia clinical trial. ZIKAVAX is driven by a strongly committed and effective consortium of four leading European organisations highly experienced in vaccine research and development. Its partners include the European Vaccine Initiative, Institut Pasteur, Themis Bioscience GmbH and the Institute of Emerging Diseases and Innovative Therapies from the Commissariat à l’Energie Atomique.

 Deliverables

List of deliverables.
Launch of the website Websites, patent fillings, videos etc. 2019-05-30 15:16:10

Take a look to the deliverables list in detail:  detailed list of ZIKAVAX deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZIKAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZIKAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

HEAP (2020)

Human Exposome Assessment Platform

Read More  

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More